ASSESSMENT OF INDUCED SPUTUM

诱发痰的评估

• 批准号: 7604596
• 负责人: Pamela L. Zeitlin
• 金额: $ 0.05万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604596
• 关键词: Address; Anti-Inflammatory Agents; Anti-inflammatory; Clinical; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Control Groups; Elastases; Funding; Grant; Ibuprofen; Institution; Measures; Outcome Measure; Pancreatic Elastase; Property; Recovery; Research; Research Personnel; Resources; Saline; Screening procedure; Source; Specimen; Sputum; Testing; United States National Institutes of Health; Upper arm; Week; celecoxib; cystic fibrosis patients; cytokine; neutrophil; treatment duration

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To determine whether neutrophils, active elastase, and cytokines measured in sputum induced using hypertonic saline are useful screening tests for determining if a particular agent with known anti-inflammatory properties is a suitable candidate for more extensive clinical trials in patients with CF. This aim will be addressed using one anti-inflammatory agent, ibuprofen, that has been shown to have clinical benefit in CF, and one anti-inflammatory agent, celecoxib, that has potential to have clinical benefit in CF. A "no treatment" arm will be included as the control group. The outcome measures will be assessed in induced sputum specimens before (Baseline Period), during (Treatment Period), and after (recovery Period) a 4-week treatment period in clinically stable CF patients. Changes will be assessed within each arm and between arms.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 确定使用高渗盐水诱导的痰液中测量的中性粒细胞、活性弹性蛋白酶和细胞因子是否是有用的筛选试验，以确定具有已知抗炎特性的特定药物是否适合在 CF 患者中进行更广泛的临床试验。这一目标将通过使用一种抗炎药布洛芬和一种抗炎药塞来昔布来实现，布洛芬已被证明对 CF 具有临床益处，而塞来昔布可能对 CF 具有临床益处。 “未治疗”组将被纳入作为对照组。将在临床稳定的 CF 患者的 4 周治疗期之前（基线期）、期间（治疗期）和之后（恢复期）对诱导痰标本进行结果测量评估。将评估每个臂内和臂间的变化。